Literature DB >> 3292106

Altered vancomycin dose vs. serum concentration relationship in burn patients.

J C Garrelts1, J D Peterie.   

Abstract

Drug elimination in patients sustaining serious thermal injury may be altered, resulting in an increased clearance and shortened half-life. Nine burn and eight medical/surgical patients with normal renal function were studied prospectively. Doses were adjusted to achieve peak and trough vancomycin serum concentrations within a narrow range. No significant difference between the groups was noted in terms of demographic characteristics, creatinine clearance, or vancomycin serum concentrations. However, the difference in daily dose needed to maintain the specified serum concentrations was significantly greater for burn patients (p less than 0.02). Burn patients also had to be dosed significantly more often than medical/surgical patients to achieve peak and trough vancomycin serum concentrations within the desired range (p less than 0.02). The elimination half-life in burn patients was significantly shorter than that in control patients (p less than 0.001). Because of the unusually high dosage requirements in burn patients, along with their poor predictability, individualization of therapy with vancomycin serum concentrations is recommended to ensure a successful therapeutic outcome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292106     DOI: 10.1038/clpt.1988.105

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

3.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 4.  Pathophysiology and pharmacokinetics following burn injury.

Authors:  P L Bonate
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

5.  Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.

Authors:  Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich
Journal:  Can J Hosp Pharm       Date:  2010-05

6.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

7.  Pharmacokinetics of cefepime in patients with thermal burn injury.

Authors:  C R Bonapace; R L White; L V Friedrich; E D Norcross; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

Review 8.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

Authors:  M J Rybak; L M Albrecht; J R Berman; L H Warbasse; C K Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 10.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.